Predicting MEK Inhibitor Response in Lung Cancer: A Proper Signature Is Required. Academic Article uri icon

Overview

abstract

  • The ERK signaling pathway is one of the most commonly deregulated pathways in cancer. Assays that accurately measure ERK signaling output in clinical specimens would be extremely helpful not only in determining the pharmacodynamic effects of drug treatment but also in selecting those patients most likely to respond to therapy. Clin Cancer Res; 23(6); 1365-7. ©2016 AACRSee related article by Brant et al., p. 1471.

publication date

  • December 6, 2016

Research

keywords

  • Lung Neoplasms
  • MAP Kinase Signaling System
  • Protein Kinase Inhibitors

Identity

Scopus Document Identifier

  • 85016155057

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-16-2576

PubMed ID

  • 27923842

Additional Document Info

volume

  • 23

issue

  • 6